{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:45:52Z","timestamp":1782456352407,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To address the limitations of egg-based influenza vaccine production, serum-free suspension culture of Madin-Darby Canine Kidney cells (MDCK) has emerged as a promising alternative. In this study, a quadrivalent influenza virus subunit vaccine was developed using this platform by culturing four viral strains, followed by purification, inactivation, and formulation. Preclinical safety evaluations in rats, rabbits, and guinea pigs demonstrated no systemic toxicity. In mice, immunization with the vaccine elicited significant hemagglutination inhibition and microneutralization antibodies against H1N1, H3N2, BY, and BV strains at 28 and 42 days post-vaccination. These results indicate that the vaccine candidate possesses a favorable safety profile and induces robust immunogenicity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1827059","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:38Z","timestamp":1782452798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical immunogenicity and safety evaluation of MDCK cell-derived quadrivalent influenza virus subunit vaccine"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuang","family":"Li","sequence":"first","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Lv","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Li","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Yan","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Sui","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Wu","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.04003","article-title":"Global and national influenza-associated hospitalisation rates: estimates for 40 countries and administrative regions","volume":"13","author":"Paget","year":"2023","journal-title":"J Glob Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.034","article-title":"The road to a more effective influenza vaccine: up to date studies and future prospects","volume":"35","author":"Sano","year":"2017","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.078","article-title":"Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses","volume":"26","author":"Russell","year":"2008","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/vaccines5030018","article-title":"Egg-inde-predent influenza and vaccines and vaccine candidates","volume":"5","author":"Manini","year":"2017","journal-title":"Vaccines Bsl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by eggadapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","unstructured":"Avian influenza outbreaks reduced egg production, driving prices to record highs in 2022\n          \n          \n          \n          2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-2694.2018.00.153","article-title":"Research progress of influenza vaccine","volume":"34","author":"Yan","year":"2018","journal-title":"Chin J Zoo"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.009","article-title":"Ovalbumin content of influenza vaccines","volume":"125","author":"Li","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B10","unstructured":"CDC vaccine price list\n          \n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2015.04.005","article-title":"Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines","volume":"204","author":"Shin","year":"2015","journal-title":"Virus Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.24","article-title":"Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production","volume":"11","author":"Montomoli","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2330643","article-title":"Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine","volume":"23","author":"Ian","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2018.1500570","article-title":"How far have we reached in development of effective influenza vaccine","volume":"37","author":"Looi","year":"2018","journal-title":"Int Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141686","article-title":"Serum-free suspension culture of MDCK cells for production of influenza H1N1 vaccines","volume":"10","author":"Huang","year":"2015","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.044","article-title":"Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor","volume":"32","author":"Tapia","year":"2014","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4134-2","article-title":"Functional evaluation for adequacy of MDCK-lineage cells in influenza reasearch","volume":"12","author":"Tsai","year":"2019","journal-title":"BMC Res Notes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.128","article-title":"Continuous cell lines as a production system for influenza vaccines","volume":"8","author":"Genzel","year":"2009","journal-title":"Exp Rev Vaccines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1586\/14760584.2015.1039520","article-title":"Flucelvax(Optaflu) for sessonal influenza","volume":"14","author":"Manini","year":"2015","journal-title":"Exp Rev Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19020818","article-title":"Relative effectiveness of cell-cultured versus egg-based seasonal influenza vaccines in preventing influenza-related outcomes in subjects 18 years old or older: a systematic review and meta-analysis","volume":"19","author":"Puig-Barber\u00e0","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B21","volume-title":"General principles for technical review of preclinical safety evaluation of preventive biological products","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.03.010","article-title":"Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC","volume":"42","author":"Ch\u00eane","year":"2019","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41541-024-00980-3","article-title":"Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines","volume":"9","author":"Hauguel","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B24","volume-title":"Technical guidelines for the study of drug irritation, hypersensitivity, and hemolysis","year":"2014"},{"key":"B25","volume-title":"Technical guidelines for non-clinical studies of preventive vaccines (General principles for technical review of preclinical safety evaluation of preventive biological products)","year":"2005"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1737456","article-title":"Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models","volume":"16","author":"Ye","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B27","article-title":"Consideration on the technical evaluation of clinical trial of seasonal influenza inactivated vaccine","volume":"24","author":"Wang","year":"2015","journal-title":"China J New Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1086\/656578","article-title":"Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults","volume":"51","author":"Frey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa371","article-title":"Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018","volume":"71","author":"Boikos","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.023","article-title":"A randomized controlled trial of antibody response to 2018-19 cell-based vs.egg-based quadrivalent inactivated influenza vaccine in children","volume":"38","author":"Moehling","year":"2020","journal-title":"Vaccine"},{"key":"B31","article-title":"WHO guidelines on non-clinical evaluation of vaccines, Annex 1","volume-title":"WHO Technical Report Series, No. 927","year":"2005"},{"key":"B32","unstructured":"The technical review general principles for preclinical safety evaluation of preventive biological products\n          \n          \n          \n          2004"},{"key":"B33","article-title":"A study on the safety and immunogenicity of quadrivalent influenza virus split vaccine","volume":"25","author":"Tan","year":"2019","journal-title":"J Anhui Prev Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2416779","article-title":"Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine","volume":"393","author":"Fitz-Patrick","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:43Z","timestamp":1782452803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1827059"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1827059","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1827059"}}